CN Patent

CN119161484A — 抗asgr1单克隆抗体及其应用

Assigned to Kelan Shanghai Pharmaceutical Technology Co ltd · Expires 2024-12-20 · 1y expired

What this patent protects

本发明公开抗ASGR1单克隆抗体及其用途。本发明进一步公开了包括抗ASGR1单克隆抗体在内的ASGR1抑制剂与第二降脂药的组合在降低血液和/肝脏中总胆固醇和/或甘油三酯的水平或治疗和/或预防心血管病中的应用。本发明证实ASGR1抑制剂与第二降脂药的组合具有协同的降低血清和肝脏中的总胆固醇和甘油三酯的作用。

USPTO Abstract

本发明公开抗ASGR1单克隆抗体及其用途。本发明进一步公开了包括抗ASGR1单克隆抗体在内的ASGR1抑制剂与第二降脂药的组合在降低血液和/肝脏中总胆固醇和/或甘油三酯的水平或治疗和/或预防心血管病中的应用。本发明证实ASGR1抑制剂与第二降脂药的组合具有协同的降低血清和肝脏中的总胆固醇和甘油三酯的作用。

Drugs covered by this patent

Patent Metadata

Patent number
CN119161484A
Jurisdiction
CN
Classification
—
Expires
2024-12-20
Drug substance claim
No
Drug product claim
No
Assignee
Kelan Shanghai Pharmaceutical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.